The U.K.’s Medicines & Healthcare Products Regulatory Agency is cautioning people who CBD products, reporting that individuals who suffered harmful side effects following consumption ballooned to 56 in 2019 from just four in 2017.
According to the Daily Mail, the agency cites individuals between the ages of 50 and 59 as reporting a big chunk of the “adverse drug reactions”, numbering 28 since 2007.
The article does not specify the specific types of adverse reactions, but WebMD notes that reported side effects of using CBD have included dry mouth, low blood pressure, lightheadedness and drowsiness. Though less common, signs of liver injury have also been reported in some patients, the information adds.
Although a study last year in Case Reports in Ophthalmological Medicine has raised plenty of questions, researchers explored an incident involving a 56-year-old woman in the U.S. who died after experiencing drug-induced Stevens-Johnson Syndrome after consuming a commercial CBD product that had not been approved by the U.S. Food and Drug Administration.
“The use of a commercial CBD product should be cautioned due to potential for a series of drug reactions to the cannabis product and the risk for reaction to other unregulated other pharmacological components,” study authors wrote.
In June of 2019, the Centre for Medicinal Cannabis (CMC) called on U.K. politicians, policymakers, regulators, producers and retailers to each play their part to help ensure the CBD sector is innovative, responsible and high-quality.
“The wave of popularity around CBD, which offers huge opportunity for the U.K. itself, now needs to be grounded on a strong foundation of research, proportionate regulation and quality standards,” CMC founder and strategic counsel Steve Moore said at the time.